Full-Time

Finance Analyst

Posted on 4/3/2025

Abzena

Abzena

201-500 employees

Supports biopharmaceutical development and manufacturing

Compensation Overview

$50k - $70k/yr

Junior, Mid

San Diego, CA, USA

Category
Financial Planning and Analysis (FP&A)
Finance & Banking
Required Skills
Financial analysis
Excel/Numbers/Sheets
Financial Modeling
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Abzena referral from your network.

đź’ˇ

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Bachelor’s degree in Finance, Accounting, Business Administration, or a related field.
  • 2+ years of relevant experience in financial analysis, budgeting, and forecasting, preferably in a manufacturing or corporate finance environment.
  • Strong knowledge of financial planning, budgeting, cost accounting, and GAAP principles.
  • Proficiency in financial software and Enterprise Resource Planning (ERP) systems.
  • Advanced Excel skills and experience with financial modeling.
  • Strong analytical and problem-solving abilities with attention to detail.
  • Ability to communicate financial concepts effectively to non-financial stakeholders.
  • Proactive mindset with the ability to work independently and as part of a team.
Responsibilities
  • Collaborate with various business unit leaders to provide financial insights and support cross-functional initiatives.
  • Analyze financial performance, identify trends, action on variances and develop recommendations to improve financial outcomes.
  • Assist in financial forecasting, budgeting, and planning cycles, ensuring alignment with site and company business objectives.
  • Prepare and present monthly management and department reports, including variance analysis between actuals, budget, and forecasts.
  • Conduct cost analysis and monitor key financial metrics to drive accountability and efficiency.
  • Support the financial close process, ensuring accuracy and completeness of month-end and year-end financial reporting.
  • Assist in maintaining financial controls, policies, and procedures to ensure compliance with GAAP and internal standards.
  • Develop financial models and tools to support strategic planning and operational decision-making.
  • Partner with operational teams to assess financial implications of business initiatives and cost-saving strategies.
  • Perform other finance business partner duties as assigned.

Abzena supports the development and manufacturing of biopharmaceutical products, working with clients such as biopharmaceutical companies and academic groups globally. The company provides a range of services that cover the entire drug development process, from discovery to clinical development, with a focus on biologics, which are drugs derived from living organisms. Abzena is known for its technologies that aid in creating antibodies currently in clinical trials. Its services include custom synthesis, high-potency active pharmaceutical ingredient (HPAPI) synthesis, and antibody-drug conjugate (ADC) manufacturing, among others. What sets Abzena apart from competitors is its comprehensive suite of specialized services and proprietary technologies that cater to the unique needs of its clients. The company's goal is to help clients develop better treatments for patients while maintaining long-term partnerships that provide recurring revenue.

Company Size

201-500

Company Stage

IPO

Headquarters

Babraham, United Kingdom

Founded

2001

Simplify Jobs

Simplify's Take

What believers are saying

  • Expansion of AI-driven drug discovery accelerates viable drug candidate identification.
  • Advancements in ADC technology increase demand for Abzena's specialized services.
  • Personalized medicine trends boost demand for Abzena's custom synthesis and analytical services.

What critics are saying

  • Emerging competitors threaten Abzena's market share in analytical and bioconjugation services.
  • Rapid technological advancements require continuous investment, straining financial resources.
  • Supply chain vulnerabilities could disrupt Abzena's operations.

What makes Abzena unique

  • Abzena offers end-to-end services for complex biologics and bioconjugates.
  • The company provides unique ADC manufacturing and bioconjugation capabilities.
  • Abzena's EpiScreen 2.0 tool enhances immunogenicity assessment for biologics and bioconjugates.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

↓ -1%

1 year growth

↑ 0%

2 year growth

↓ -2%
Abzena
Apr 24th, 2025
Abzena's Customer Archetype Therapeutics to Present at AACR 2025 on Lung Cancer Drug Candidate Results

Archetype is partnering with contract research organizations (CROs) Abzena and Alloy Therapeutics, to design and develop Antibody-drug conjugates (ADCs) using some of the clinical stage and approved targeted therapy small molecules featured in the presentation.

PR Newswire
Feb 26th, 2025
Abzena Strengthens Executive Leadership Team With The Appointment Of Taylor Boyd As Cbo

SAN DIEGO, Calif., Feb. 26, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today that Taylor Boyd has joined the company as its Chief Business Officer ("CBO"). In this newly created role, Boyd will be responsible for corporate development, portfolio strategy, and partnering strategy activities that drive Abzena's continued commitment to innovation and growth

Contract Pharma
Feb 26th, 2025
Abzena Appoints Taylor Boyd as CBO

Abzena, an integrated CDMO + CRO for complex biologics and bioconjugates, has named Taylor Boyd Chief Business Officer.

CityBiz
Jan 8th, 2025
Abzena Appoints Dr Moncef Slaoui to Board

SAN DIEGO, Jan. 8, 2025 /PRNewswire/ - Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has today announced the appointment of Dr Moncef Slaoui, PhD, to its Board of Directors.

PR Newswire
Jan 8th, 2025
Abzena Strengthens Board With Appointment Of Biopharma Industry Leader, Dr Moncef Slaoui

SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has today announced the appointment of Dr Moncef Slaoui, PhD, to its Board of Directors. A highly accomplished leader in the biopharmaceutical industry with over 40 years' experience, Dr Slaoui has held numerous executive leadership and board level positions, to help drug development companies through high phases of growth.Matt Stober, CEO of Abzena said, "Dr Slaoui's exceptional track record of leadership and expertise in product innovation will be extremely valuable as we continue to grow and position ourselves as the leading drug development and manufacturing organization for complex biologics and bioconjugates. We welcome him to our board and look forward to leveraging his extensive experience in supporting high–growth pharmaceutical businesses.""I am thrilled to be joining Abzena's Board of Directors," said Slaoui. "Abzena is a true innovator in the CRO and CDMO space, and I look forward to helping them develop new technologies and platforms that enable the better delivery of next gen therapeutics.""I am delighted that Moncef has accepted this position," said Geoffrey Glass, Chairman of Abzena's Board. "Moncef brings a set of highly relevant skills and experience to the board, and I look forward to working with him and our executive team as we support Abzena through its next stage of growth."Dr Moncef Slaoui currently serves as an advisor to Medicxi and is on the Board of Directors of several companies including Cedar Health, Arcturus Therapeutics, Altesa, Zephyr AI and Vicebio

INACTIVE